Transplant Genomics is Drug Delivery in United States that focus on developer business. Founded in 2013. They cover business area such as developer, molecular diagnostic test, kidney and liver graft dysfunction, robust molecular signature, individual patient graft status, prognosis, response, specific immunosuppressant regimen, histological analysis, doctor, organ transplant outcome, noninvasive serial monitoring, genomic.
2013
( 11 years old in 2024 )
Developer
-
905 South Main Street
Suite 202
Mansfield, MA 02048
United States
Private
developermolecular diagnostic testkidney and liver graft dysfunctionrobust molecular signatureindividual patient graft statusprognosisresponsespecific immunosuppressant regimenhistological analysisdoctororgan transplant outcomenoninvasive serial monitoringgenomic
* We use standard office opening hours in near Transplant Genomics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Transplant Genomics is Drug Delivery business from United States that founded in 2013 (11 years old in 2024), Transplant Genomics business is focusing on Developer.
Transplant Genomics headquarter office and corporate office address is located in 905 South Main Street Suite 202 Mansfield, MA 02048 United States.
Transplant Genomics was founded in United States.
In 2024, Transplant Genomics is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Transplant Genomics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
